Adherence management has never been easier

A clinically proven solution that meets
the needs of your largest patient group.1

With a simple to manage remote consultation model
that allows you to easily extend your therapy portfolio.

What is NMES?
Schedule a demo
  • 52% reduction in AHI**
  • 50% reduction in ODI**
  • 3.9 point reduction in ESS**

Complete your armamentarium

eXciteOSA reduces primary snoring and mild osa by retraining the upper airway.2,3,5

No other device currently on the market does this.

  • Treat patients with primary snoring and mild OSA with eXciteOSA
  • Early treatment may slow progression or possibly delay the need for other treatments

A simple way to manage patients

Ease of therapy + App-directed support = Patient adherence

eXciteOSA is clinically proven to reduce apneas**

A published study found a reduction of 52% in AHI and 50% in ODI amongst the patient subset who responded to therapy, all without a night-time wearable.

You can monitor and manage progress remotely

The eXcite portal allows for remote tracking to support patient adherence.

The portal

Ease of therapy encourages patient adherence

It’s easy for patients to find 20 mins in their daily schedule. Real world adherence is >80%.4

How it works

Are you ready to offer your patients a therapy that is simple, convenient and clinically proven?

Find out how easy it is to integrate eXciteOSA into your treatment continuum for primary snoring and mild osa.

If you are an existing eXciteOSA patient, please contact us here.

    By submitting this form I acknowledge that the data I provide will be transferred to eXciteOSA for the purpose of keeping me informed of eXciteOSA® news.

    How It Works

    eXciteOSA helps
    the body help itself

    By addressing muscle function, eXciteOSA is unlike traditional therapies.

    null

    Using Neuromuscular Electrical Stimulation (NMES), the mouthpiece targets and retrains the tongue in order to increase muscle endurance.

    Six weeks of treatment is associated with a significant increase in endurance of the tongue muscle.5 Patients experience a noticeable reduction in symptoms after 6 weeks.2,3,6

    Watch a video of an overview of eXciteOSA clinical evidence

    The Portal

    Supporting and managing your
    eXciteOSA patients has never been easier

    Using the portal, you can easily analyse and reference your patients’
    usage patterns, trends and statistics during in-person or telehealth appointments.

    null

    Valuable insights

    An array of interactive reports using proprietary algorithms, highlight relevant usage insights that suit your needs.

    Focused activity

    The dashboard reflects real-time eXciteOSA app data, allowing you to focus only on those patients who need help.

    Remote patient management

    As telehealth becomes the norm and not the exception, the patient dashboard is a useful no cost tool for remote consultation and management.

    Schedule a
    demonstration

    See how eXciteOSA will benefit your patients.

    • 52% reduction in AHI**
    • 50% reduction in ODI**
    • 3.9 point reduction in ESS**

      By submitting this form I acknowledge that the data I provide will be transferred to eXciteOSA for the purpose of keeping me informed of eXciteOSA® news.

      Backed by Experts

      Trusted by sleep specialists

      “We believe that eXciteOSA® therapy will be able to help many patients in the near future.”

      — Dr. Marina Carrasco-Llatas

      • Specialist in ORL at Dr. Peset University Hospital, Valencia, Spain
      • Expert in Sleep Medicine
      • President of the Commission on Roncopathy and Sleep Apnoea of the Spanish Society of Otolaryngology and Head and Neck Surgery
      Atul Malhotra

      “I am optimistic that this treatment will be an important treatment approach for patients with with mild sleep apnea and snoring.”

      — Professor Atul Malhotra

      • M.D. Research Chief, Pulmonary, Critical Care and Sleep Medicine
      • Peter C. Farrell Presidential Chair and Professor in Respiratory Medicine
      • Former President, American Thoracic Society 2015- 2016

      Signifier Medical Technologies is focused on the development and commercialization of innovative solutions for patients with snoring and sleep-disordered breathing conditions.

      Pioneers in challenging the wisdom of conventional snoring and sleep apnea treatments, we’ve created the first daytime therapy that tackles the root cause of sleep-disordered breathing by physiologically retraining the airway against collapse.

      Newsletter sign-up

      Not ready to get started, or already started? Sign up to our newsletter to be kept up to date on the many advances in NMES to treat OSA and primary snoring. We don’t spam.

        By submitting this form I acknowledge that the data I provide will be transferred to eXciteOSA for the purpose of keeping me informed of eXciteOSA® news.

        References

        1. Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pepin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019;7:687-698.
        2. Wessolleck, E., Bernd, E., Dockter, S. et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie 22, 47–52 (2018). https://doi.org/10.1007/s11818-018-0179-z
        3. Kotecha, B., Wong, P.Y., Zhang, H. et al. A novel intraoral neuromuscular stimulation device for treating sleep-disordered breathing. Sleep Breath (2021). https://doi.org/10.1007/s11325-021-02355-7
        4. Data on File. Signifier Medical Technologies, 2021
        5. Based on analysis of n=20 participants with primary snoring and mild OSA recruited from a single site in the US, who underwent a single-arm trial of eXciteOSA for a duration of six weeks between July 2019 and February 2020. Polysomnography and functional assessments of tongue strength and endurance were conducted at baseline and follow-up. Data on file.
        6. Baptista, Peter M., Paula Martínez Ruiz de Apodaca, Marina Carrasco, Secundino Fernandez, Phui Y. Wong, Henry Zhang, Amro Hassaan, and Bhik Kotecha. 2021. “Daytime Neuromuscular Electrical Therapy of Tongue Muscles in Improving Snoring in Individuals with Primary Snoring and Mild Obstructive Sleep Apnea” Journal of Clinical Medicine 10, no. 9: 1883. https://doi.org/10.3390/jcm10091883

        *See For Sleep Apnea page
        **Based on analysis of n=65 participants with mild OSA recruited from multiple UK and European sites, who underwent a single-arm trial of eXciteOSA for a duration of six weeks between February 2019 and April 2020. A subset of n=51 responders experienced a 52% reduction in AHI, a 50% reduction in ODI, and a 3.9 point reduction in ESS. Data on file.